Research Reports | Market Assessment
September 2016

Rheumatoid Arthritis | Current Treatment: Physician Insights | EU5 | 2016

Five TNF-α inhibitors and four biologics with alternative mechanisms of action are currently approved for the treatment of rheumatoid arthritis (RA) in the EU5 (France, Germany, Italy, Spain, United Kingdom). The TNF-α inhibitors are the most widely prescribed biologics in RA patients refractory to conventional DMARDs owing to their efficacy, postmarketing safety data, and physicians’ familiarity with them. However, the high-priced, branded TNF-α inhibitors face a competitive threat from the recent launch of biosimilars, including biosimilar infliximab and biosimilar etanercept, which provide cost-effective alternatives. The Rheumatoid Arthritis Current Treatment (EU5) content provides in-depth analysis of rheumatologists’ treatment and prescribing practices in the crowded RA market, including drivers of treatment selection, obstacles to biologics use, analysis of patient share, and anticipated changes in drug usage.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports